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Clinical Investigation
Introduction
Traditional self-expanding stent-grafts require an infrarenal 
nonaneurysmal aortic neck to adequately seal the abdomi-
nal aortic aneurysm (AAA) sac from chronic circulatory 
pressures. Sealing is obtained by oversizing the stent-graft 
(from 10% to 30%) at that level, on the assumption that the 
chronic radial force exerted longitudinally against the aortic 
wall will circumferentially avert any leakage. Since the first 
endovascular aneurysm repair (EVAR) experiences, this 
sealing concept has restricted the application of stent-grafts 
to patients with a proximal aortic neck generally longer than 
15 mm.1 In patients with complex aortic necks, proximal 
graft sealing remains a challenge with traditional self-
expanding stent-grafts.2–5 In particular, a recent systematic 
review and meta-analysis reported that short neck and AAA 
diameter are strongly associated with migration, subsequent 
proximal type Ia endoleak, and poor early and late out-
comes after EVAR.6
The Ovation endograft (Endologix, Irvine, CA, USA), 
with its new concept of sealing by nonexpansive circum-
ferential apposition of polymer-filled rings to the aortic 
wall, generates no chronic outward force at the infrarenal 
aortic level.7 In August 2010, the Ovation endograft 
received Conformité Européenne approval and was com-
mercially accessible in Europe. At that time, the device-
specific instructions for use (IFU) allowed the treatment of 
aneurysms with a proximal aortic neck of only 7 mm, the 
first device ever approved for necks shorter than 10 mm.
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Abstract
Purpose: To compare the use of the Ovation stent-graft according to the ≥7-mm neck length specified by the original 
instructions for use (IFU) vs those treated off-label (OL) for necks <7 mm long. Methods: A multicenter retrospective registry 
(TriVascular Ovation Italian Study) database of all patients who underwent endovascular aneurysm repair with the Ovation 
endograft at 13 centers in Italy was interrogated to identify patients with a minimum computed tomography (CT) follow-up of 
24 months, retrieving records on 89 patients (mean age 76.4±2.4 years; 84 men) with a mean follow-up of 32 months (range 
24–50). Standard CT scans (preoperative, 1-month postoperative, and latest follow-up) were reviewed by an independent core 
laboratory for morphological changes. For analysis, patients were stratified into 2 groups based on proximal neck length ≥7 mm 
(IFU group, n=57) or <7 mm (OL group, n=32). Outcome measures included freedom from type Ia endoleak, any device-related 
reintervention, migration, and neck enlargement (>2 mm). Results: At 3 years, there was no aneurysm-related death, rupture, 
stent-graft migration, or neck enlargement. There were no differences in terms of freedom from type Ia endoleak (98.2% IFU 
vs 96.8% OL, p=0.6; hazard ratio [HR] 0.55, 95% CI 0.02 to 9.71 or freedom from any device-related reintervention (92.8% 
IFU vs 96.4% OL, p=0.4; HR 2.42, 95% CI 0.34 to 12.99). In the sealing zone, the mean change in diameters was −0.05±0.8 mm 
in the IFU group and −0.1±0.5 mm in the OL group. Conclusion: Use of the Ovation stent-graft in patients with neck length 
<7 mm achieved midterm outcomes similar to patients with ≥7-mm-long necks. These midterm data show that the use of the 
Ovation system for the treatment of infrarenal abdominal aortic aneurysm is not restricted by the conventional measurement 
of aortic neck length, affirming the recent Food and Drug Administration–approved changes to the IFU.
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The circumferential sealing of the Ovation endograft 
based on the polymer-filled ring theoretically allows the 
treatment of a range of aortic neck diameters independent of 
neck length. This means that even in the presence of an aor-
tic neck length <7 mm, some patients can be treated pro-
vided that the aortic neck diameter is compatible with the 
Ovation ring sizes. This study compared the outcomes of 
the Ovation stent-graft applied according to the neck length 
required by the original IFU vs off-label (OL) use (neck 
length <7 mm).
Methods
Study Registry and Patient Sample
A multicenter registry (TriVascular Ovation Italian Study) 
database was established to retrospectively gather data on 
all patients who underwent EVAR with an Endologix 
Ovation endograft at 13 centers in Italy from 2010 onward 
(see the appendix for a list of collaborators). The initial 
manufacturer’s IFU recommended a nonaneurysmal proxi-
mal aortic neck with (1) a length of at least 7 mm proximal 
to the aneurysm, (2) an inner diameter between 16 and 30 
mm, and (3) an aortic angle ≤60° for a proximal neck ≥10 
mm long or ≤45° for a proximal neck <10 mm in length.
For this analysis, the database was searched to identify 
patients with a minimum computed tomography (CT) fol-
low-up of 24 months, which retrieved 89 patients (mean age 
76.4±2.4 years; 84 men) treated from December 2010 to 
November 2012 who met the inclusion criterion. Mean fol-
low-up was 32 months (range 24–50). Patients were strati-
fied into 2 groups based on proximal neck length ≥7 mm 
(IFU group, n=57) or <7 mm (OL group, n=32).
Image Analysis and Measurements
Full datasets and cross-sectional images of the contrast-
enhanced CT scans performed before EVAR, at the first 
postoperative month, and at the latest follow-up were 
reviewed centrally by a vascular surgeon (GdD) using dedi-
cated software with multiplanar and volume reconstructions 
(OsiriX MD v.6.5.1 64-bit; Pixmeo SARL, Bernex, 
Switzerland). All vessel measurements (outer wall to outer 
wall) were performed using a central line lumen created by 
manual segmentation of the aorta on each axial slice. In 
addition to the dimensions of the aorta, the presence of 
thrombus, graft migration, stent-graft patency and integrity, 
evidence of endoleak, barb detachment, and ventral, lateral, 
and posterior neck bulging were assessed. The proximal aor-
tic neck on scans after EVAR was evaluated in 2 distinct 
zones: (1) the collar zone from a tangential horizontal plane 
passing through the most distal point of the circumference of 
the lowermost renal artery ostium to a horizontal plane pass-
ing through the most cranial point of the first polymer-filled 
ring and (2) the sealing zone at the level of the first polymer-
filled ring. These 2 zones were examined separately and then 
compared between pre- and postoperative images, with the 
distance from the lower renal artery as reference for the anal-
ysis of morphological changes of each single zone. The 
same imaging data were sent to a centralized core laboratory 
for independent review of morphological changes.
Definitions
The AAA neck was defined as the longitudinal distance 
between the first transverse CT slice directly distal to the 
lowermost renal artery and the first transverse CT slice that 
showed at least a 10% larger outer aortic wall diameter vs 
the diameter measured directly below the lowermost renal 
artery. Aortic neck dilatation referred to a diameter increase 
>2 mm between the preoperative and latest follow-up CT 
scan. Stent-graft migration was defined as a ≥3-mm increase 
in the distance between the lower renal artery and the proxi-
mal end of the stent-graft between the first and latest CT 
scan.
Primary technical success (intention-to-treat basis) 
referred to successful introduction and deployment of the 
device in the absence of surgical conversion, death, type I or 
III endoleaks, or graft limb obstruction. Assisted primary or 
secondary technical success referred to the use of unplanned 
endovascular or surgical procedures, respectively, to achieve 
a successful procedure.
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Clinical success was defined as satisfactory deployment 
of the endovascular device at the intended location without 
death as a result of aneurysm-related treatment, type I or III 
endoleak, graft infection or thrombosis, aneurysm expan-
sion (diameter >5 mm or volume >5%), aneurysm rupture, 
or conversion to open repair. Assisted primary and second-
ary clinical success referred to re-establishment of patency 
or resolution of a complication by endovascular or surgical 
means, respectively. Secondary interventions included both 
endovascular and surgical procedures.
AAA-related adverse events referred to a composite of 
direct (type I or III) or undetermined type endoleaks, aneu-
rysm sac growth, migration, device integrity failure, AAA-
related death, late post-implantation AAA rupture, or any 
AAA-related secondary intervention.
Outcome Measures
The primary study outcome was freedom from type Ia 
endoleak; secondary outcomes were primary clinical suc-
cess, freedom from any device-related reintervention, free-
dom from rupture, freedom from migration, and freedom 
from neck dilatation (>2 mm) in the collar and sealing 
zones.
Statistical Analysis
The data were expressed as mean ± standard deviations or 
as median and interquartile range (IQR), depending on the 
type of distribution. Intraobserver variability was assessed 
using Cohen’s kappa (κ) test of concordance based on the 
observer measuring each of 20 randomly selected CT scans 
twice at least 2 weeks apart. The mean changes in the diam-
eters at the collar and sealing zones are presented with the 
standard error of the mean (SEM). The Spearman rank cor-
relation coefficient (ρ) was used to test for any relationship 
between these changes at the collar and sealing zones. The 
Kaplan-Meier method was used to analyze the outcome 
measures; competing risk analysis was used for all compli-
cations.8–10 Curves for the 2 groups were compared with the 
log-rank test. The estimates are given along with the hazard 
ratio (HR) and the 95% confidence intervals (CI). All statis-
tical analyses were performed using GraphPad Prism statis-
tical software (GraphPad, San Diego, CA, USA).
Results
Primary technical success was 96.5% (1 type Ia endoleak 
and 1 iliac graft occlusion) in the IFU group and 96.9% (1 
type Ia endoleak) in the OL group (p=0.8). In the IFU group, 
the iliac graft occlusion was treated with a femorofemoral 
bypass (98.3% secondary technical success) and the 
endoleak was lessened after intraoperative balloon angio-
plasty; the leak had disappeared at the 1-month CT scan. 
The endoleak in the OL group was treated with a balloon-
expandable stent (100% assisted primary technical suc-
cess). The perioperative mortality was 0%.
At 2 years, primary clinical success was 94.8% and 
96.9%, respectively, in the IFU and OL groups (p=0.6). 
There was no aneurysm-related death, rupture, stent-graft 
migration, or neck enlargement. Each group had 1 late type 
Ia endoleak. The IFU group also had 2 graft thromboses. 
Reintervention was performed in 4 (7.0%) IFU patients for 
the late endoleak (coil and glue embolization), the 2 iliac 
limb occlusions (bypass in one and surgical thrombectomy 
in the other), and a type II endoleak (coil embolization). In 
the OL group, the only reintervention (3.1%) was for the 
late Ia endoleak (aortic cuff). Kaplan-Meier analysis at 3 
years (Figure 1) found no differences in terms of freedom 
from type Ia endoleak (98.2% IFU vs 96.8% OL, p=0.6; HR 
0.55, 95% CI 0.0 to 9.71) or freedom from any device-
related reintervention (92.8% IFU vs 96.4% OL, p=0.4; HR 
2.42, 95% CI 0.34 to 12.99).
In the CT image analysis, intraobserver agreement was 
excellent (Cohen’s κ=0.91). The sizes of the stent-graft 
body ranged from 23 to 34 mm; mean oversizing was not 
different in the 2 study groups (17%±4% IFU vs 19%±3% 
OL, p=0.3). The mean stent-graft landing distance to the 
lower renal artery was 3.13±4.25 mm (median 2 mm, IQR 
0,6) and did not vary between groups (3.4±4.1 IFU vs 
2.9±3.3 OL, p=0.2). In particular, landing distance (Figure 
2A) was ≤5 mm in 68.4% (39/57) of IFU patients and 81.1% 
(26/32) of OL patients (p=0.02).
Changes in the collar and sealing zones were analyzed 
in both groups. At the last follow-up scan, the mean change 
in the diameters at the collar zone (Figure 2B) was −0.3±0.7 
mm (SEM 0.07) in the IFU group and −0.2±0.8 mm (SEM 
0.08) in the OL group; the majority of cases had an abso-
lute decrease in the diameter (median 0.0 mm, IQR 0, 
−0.6). In the sealing zone (Figure 2C), the mean alterations 
in diameters were −0.05±0.8 mm (SEM 0.08) in the IFU 
group and −0.1±0.5 mm (SEM 0.1) in the OL group 
(median 0.0 mm, IQR +0.4, −0.3). Changes at the collar 
zone correlated significantly (Figure 3) with modifications 
at the sealing zone in both groups equally (IFU group: 
ρ=0.13; OL group: ρ=0.19).
Discussion
The beginning of the EVAR era was characterized by endo-
grafts that consisted of a tubular graft attached at both ends 
to a large balloon-expandable stent, such as the homemade 
Parodi endograft or the Montefiore Endograft System. Not 
surprisingly, because these early devices lacked chronic out-
ward force at the level of the proximal neck, they were not 
associated with neck dilatation over time, even though stent 
migration and endograft collapse into the sac were possible 
complications.11–13 With the advent of self-expanding 
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stent-grafts, the balloon-expandable models have been rap-
idly disappearing from the market for several years.
For a long time, the only available technology for sealing 
was based on the application of self-expanding forces to a 
portion of healthy proximal aortic neck. The recent appear-
ance of the Ovation endograft, with its unique circumferen-
tial inflatable sealing rings, represents a valid alternative to 
chronic outward forces for appropriate sealing, avoiding 
neck dilatation as previously reported for patients in our 
registry.14
Typically, the feasibility of EVAR for infrarenal AAA 
has been mainly related to the aortic morphology, with 
the majority of manufacturers’ IFU originally requiring an 
adequate nonaneurysmal proximal neck of 10 to 15 mm, an 
aortic diameter <30 mm, with infrarenal angulation <60°. 
As expected, implantations outside of the anatomical crite-
ria specified in the IFU have an incremental negative effect 
Figure 2. (A) Stent-graft landing distance to the lowest renal 
artery. (B) Changes in diameters over time at the level of the 
collar zone. The horizontal line in the middle of the box indicates 
the median; the top and the bottom borders of the box mark the 
75th and 25th percentiles, respectively. (C) Changes in diameters 
over time at the level of the sealing zone. The horizontal line 
in the middle of the box indicates the median; the top and the 
bottom borders of the box mark the 75th and 25th percentiles, 
respectively. IFU, instructions for use; OL, off-label.
Figure 1. Kaplan-Meier estimates of (A) freedom from 
type Ia endoleak and (B) freedom from reintervention in the 
instructions for use (IFU) and off-label (OL) groups.
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on late results.15,16 In a systematic review and meta-analysis 
of the literature, Spanos et al6 identified patients with large 
AAAs and short necks as those at highest risk of graft 
migration after EVAR with old-generation stent-grafts. Of 
note, neck diameter and neck angulation did not have any 
important influence on stent-graft migration.
With the availability of new generation devices, an 
increasing number of EVARs have been performed outside 
the IFU.17 Violations of the IFU are particularly focused on 
unfavorable proximal aortic neck anatomy. Out of 10,228 
patients undergoing EVAR between January 1, 1999, and 
December 31, 2008, only 42% of patients had anatomy that 
met the most conservative definition of the IFU, while 69% 
met the most liberal interpretation of the IFU.18
A systematic review and meta-analysis of outcomes 
following EVAR in patients with hostile neck anatomy 
(neck length <15 mm, diameter >28 mm, or angulation 
>60° alone or in combination) revealed a significant 
increase in 30-day (odds ratio 2.92) and late (odds ratio 
1.71) type I endoleaks in comparison with patients with 
favorable neck anatomy.2
The first endograft to be approved for proximal necks 
<10 mm when it came to market, the Ovation recently 
became the only Food and Drug Administration (FDA)–
approved abdominal aortic stent-graft to have no restriction 
on the aortic neck length in its labeling.19 Neck length is 
considered only in assessing angulation: patients with a 
proximal neck length <10 mm are eligible with an aortic 
angle ≤45°; otherwise, angles up to 60° are indicated.19
In accord with the expanded IFU, the use of the Ovation 
stent-graft in the absence of a 7-mm neck length was not 
dissimilar from midterm outcomes of the IFU group. Thus, 
the Ovation system does not require a minimum length of 
parallel vessel walls to achieve durable aneurysm seal. This 
is particularly important, since there has been no evidence 
until now that positive outcomes could be achieved based 
on the expanded IFU.
Admittedly, the good results in our registry were strictly 
related to the high familiarity of the operators with the 
device, which guaranteed a mean graft landing distance to 
the lower renal artery of only 3.13 mm. As part of a suc-
cessful Ovation endograft implantation, landing the first 
ring in a conical and short neck has to be exactly at a pre-
identified level of the aorta (typically 13 mm below the 
lower renal artery). A less precise deployment, even of 
only a couple of millimeters, may result in poor apposition 
of the sealing ring to the aortic wall. As revealed by the 
core laboratory evaluation, such a marginal and unplanned 
mistake in the endograft landing was responsible for the 
intraoperative and late type Ia endoleaks in the 2 OL 
patients.
Data on neck stability, both in the collar and sealing 
zones, emphasize how the aortic neck can definitely main-
tain its diameter with a sealing technology that does not 
apply chronic outward force. In particular, the permanence 
of the diameters at the level of the collar zone in the OL 
patients and correlation with the positive remodeling occur-
ring at the level of the sealing zone seem to confirm that 
both areas are protected by blood pressure and do not 
expand as a result of the absence of any chronic radial force. 
Finally, our data clearly support the rationale of the investi-
gational Ovation Alto endograft, in which the zone between 
the suprarenal stent and the first ring is totally omitted, as 
proposed previously by Nano et al.20
Reports on anatomical suitability for EVAR21,22 vary 
between 25% and 66%, most often referring to the most 
liberal anatomical restrictions for each device. The mini-
mum neck length requirement for conventional self-expand-
ing stent-grafts and their ≥18-F outer diameter system 
profile are still the major exclusion criteria for standard 
EVAR. The present IFU for the Ovation system, with no 
proximal neck length requirement and vascular access com-
patible with a 14-F device, might increase the patient popu-
lation suitable for EVAR substantially, without elevating 
the complication rate, as demonstrated by our data.
Figure 3. The Spearman correlation test between changes 
at the collar zone and changes at the sealing zone in (A) the 
instructions for use (IFU) group vs (B) the off-label (OL) group.
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Limitations
This was a retrospective study partially limited by the 
small size of the study cohort. Only patients with a com-
pleted CT follow-up were included, which may have cre-
ated a bias since it is more likely that patients who did not 
receive CT control were those with more favorable out-
comes (ie, patients with complete sac exclusion and sig-
nificant aneurysm shrinkage at ultrasound follow-up). A 
further limitation was that a single observer performed all 
the CT analyses.
Conclusion
Use of the Ovation stent-graft in patients with neck 
length <7 mm achieved midterm outcomes no different 
from patients with ≥7-mm-long necks, proving that the 
Ovation sealing ring creates uniform, continuous wall 
apposition with a circumferential nonexpansive seal 
independent of aortic neck length. Thus, the Ovation sys-
tem may be used in aneurysm necks with an inner wall 
diameter compatible with the 16- to 30-mm size range of 
the polymer-filled rings. These data affirm the recent 
FDA-approved elimination of any neck length restriction 
in the Ovation’s IFU.
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